Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma May 21, 2026 · Financial Post About Toripalimab Read MoreVisit freshyourfeel.org for more information. Read full story at source